High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure

Johanna Lönn, Faisal Shahzad, Fredrik Uhlin, Torbjörn Bengtsson, Gabriel Almroth and Fariba Nayeri

Linköping University Post Print

N.B.: When citing this work, cite the original article.

Original Publication:
http://dx.doi.org/10.4236/abb.2012.324068
Copyright: © 2012 SciRes.
Publisher URL: http://www.SciRP.org/

Postprint available at: Linköping University Electronic Press
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-84491
High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure

Johanna Lönn1,2*, Faisal Shahzad1, Fredrik Uhlin3, Torbjörn Bengtsson2, Gabriel Almroth3, Fariba Nayeri1,4

1PEAS Institute, Linköping, Sweden
2Division of Clinical Medicine, School of Health and Medical Sciences, Örebro University, Örebro, Sweden
3Department of Nephrology UHL, County Council of Östergötland, Department of Medicine and Health Science, Faculty of Health Science, Linköping University, Linköping, Sweden
4Department of Molecular and Clinical Medicine, Division of Infectious Diseases, University Hospital, Linköping, Sweden

Email: *johanna.lonn@oru.se, johanna@peasinstitut.se

Received 30 June 2012; revised 30 July 2012; accepted 16 August 2012

ABSTRACT

Hepatocyte growth factor (HGF) is a renotropic, antifibrotic and regenerative factor with cytoprotective effects that is produced by mesenchymal cells and shows high affinity to components of extra cellular matrix, such as heparan sulphate proteoglycan (HS-PG), in healthy. Patients with chronic renal failure (CRF) suffer from a chronic inflammatory disorder. In order to assess the underlying mechanisms for development of CRF we aimed to assess the amounts and affinity of HGF in this patient group. ELISA, western blot and surface plasmon resonance (SPR) were used to study HGF in blood samples, as well as in isolated neutrophils, in CRF patients compared to healthy controls. Patients with CRF showed higher HGF levels in serum (P < 0.0001), but decreased affinity to HSPG (P < 0.0001). Addition of protease inhibitors decreased the difference between patients with CRF compared to healthy individuals. HGF with potent regenerative function during injury lacks affinity to HSPG in patients with CRF that may depend on production of proteases from activated immune cells. This information might be used to highlight underlying mechanisms for chronicity and leading to new strategies for treatment of chronic injuries.

Keywords: Chronic Renal Failure; Hepatocyte Growth Factor; Biological Activity; Neutrophils

1. INTRODUCTION

Chronic renal failure (CRF) is a global public health concern, and the underlying mechanisms and factors involved in the disease development are intensively studied but still not clarified. Non reversible damage of parenchymal tissue and renal fibrosis that ultimately leads to end-stage renal failure is the common pathogenetic mechanism in CRF. Simplified, renal fibrosis constitutes a failed wound-healing process of the kidney tissue after a chronic, sustained injury. Based on this fact we aimed to study the role of one of the most potent regenerative and anti-fibrotic factors, hepatocyte growth factor (HGF), in CRF in order to highlight the underlying mechanisms and eventually assess the therapy options.

In the genesis of chronic inflammation there is a shift in the balance between anti- and pro-inflammatory mediators, such as growth factors, their receptors, extracellular matrix molecules and proteases [1]. HGF is a renotropic and regenerative factor with cytoprotective effects that has garnered substantial attention for its protective involvement in kidney disease [2-4]. This factor is multipotent and acts on various cell types [5], and in the kidney HGF plays an important role in renal development and maintenance of normal adult kidney structure and functions, e.g. by mediating motogenic, mitogenic, morphogenic and antiapoptotic actions in renal tubular epithelial cells [2,3,6].

Prior to the initiation of renal regeneration, HGF mRNA and protein levels increase in kidneys and intact organs (such as lungs) [7,8] and HGF is released after mechanical or chemical damage [9] mainly from fibroblasts. Once tissue injury occurs, active mature HGF is produced by proteolytic processing to a heterodimeric molecule consisting of a α-chain (62 kD) and a β-chain (32 - 36 kD). As the heterodimeric form is required for HGF bioactivity, the regulation of the proteolytic cleavage of the 92 kDa single-chain precursor from, pro-HGF, is an important event to modulate HGF biological acti-
logical activity, characterized by reduced binding affinity. HGF may appear in a form with reduced bioactivity in patients with chronic kidney disease compared to a healthy control group.

2. MATERIALS AND METHODS

2.1. Study Subjects and Protocol

Thirty six patients (mean age 71.4 years; range 48 - 88 years; 30 men and 6 women) with chronic renal disease that had developed to total renal insufficiency and were on on-going haemodialysis at Linköping University Hospital between 2007 and 2012, were enrolled in this study. A control group of thirty seven subjects (mean age 39.4 years; range 19 - 65; 23 men and 14 women) were recruited from healthy blood donors. Subjects with an active infection and/or treatment with antibiotics were excluded. Peripheral venous blood was drawn, and collected in serum vacutainer tubes (Venosafe, Terumo Europe). The blood samples were centrifuged at 3000 × g for 10 minutes, the serum was collected and frozen at −70°C and later stored in −20°C. The study protocol was approved by the Regional Ethical Review Board in Linköping, Sweden, and all participants provided written, informed consent.

2.2. Isolation of Neutrophils

Blood was drawn prior to haemodialysis from patients suffering from chronic renal failure (n = 11), as well as from healthy volunteers (n = 8) into EDTA-containing (2 mg/ml) vacutainer tubes (Venosafe) at Linköping university hospital in Sweden. Polymorphonuclear cells were isolated by density centrifugation as previously described [32]. Briefly, whole blood was layered upon Polymorphprep™ (Axis-Shield PoC AS, Oslo, Norway), and PMNs were isolated through density centrifugation (480 × g, 40 min, RT). Contaminating erythrocytes were lysed using hypotonic water, after which the osmotic pressure was restored. The cells were washed (400 × g, 5 min, 4°C), counted (by using light microscope and a Bürker chamber) to get a final concentration of 1 × 10⁷ cells/ml, and re-suspended in Krebs-Ringer glucose buffer (KRG; 120 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO₄, 1.7 mM KH₂PO₄, 8.3 mM Na₂HPO₄, and 10 mM glucose, pH 7.3) supplemented with 1.1 mmol/L CaCl₂, and kept on ice until further usage.

2.3. Neutrophil Degranulation Experiment

PMNs (1 × 10⁷ cells/ml) were pre-incubated 5 min with 5 µg/ml cytochalasin B (Sigma-Aldrich, St Louis, MO, USA).
USA) at 37°C, thereafter additionally 5 min in the presence or absence of protease inhibitors (p-8340; AEBSF 40 μM, aprotinin 0.32 μM, bestatin 16 μM, E-64 5.6 μM, leupeptin 8 μM, pepstatin A 6 μM; Sigma-Aldrich), and subsequently stimulated with 10 μM N-formylmethionyl-leucyl-phenylalanine (fMLP) for 30 min. As negative control, samples without fMLP-stimulation were incubated at 37°C for 30 min. The PMN cell suspension was kept on ice and then centrifuged at 400 × g at 4°C for 10 min to get the cell-free supernatant. The supernatants were stored immediately at –20°C until further analysis.

2.4. ELISA Measurement

The HGF concentration in serum and in neutrophil suspensions was determined using an ELISA kit (Quantikine Human HGF immunoassay, minimum detectable limit: 0.04 ng/mL; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. The HGF in the neutrophil suspension was concentrated by using both a 100 kDa and a 30 kDa filter (Millipore, Solna, Sweden). All measurements were performed in duplicate at 450 nm using an ELISA reader (Expert 96; Asys Hit-GmbH, Eugendorf, Austria), and calibrated using the recombinant human HGF reference samples and standards that were provided in the ELISA kit.

2.5. SPR Measurements and Ligand Immobilisation Procedures

Biologically relevant ligands of HGF; monoclonal anti-HGF antibody (unknown epitope), recombinant HGF receptors, and D-19 goat polyclonal IgG (Table 1), were obtained commercially and immobilised on a Biacore CM5 chip (GE-Healthcare GmbH, Uppsala, Sweden). The affinity of HGF to the different ligands was analyzed by SPR, and the binding to HSPG has previously been proved to be important and correlate with the biological activity and growth in an in vitro model of cell injury and was used in this study to evaluate the biological activity of HGF [28,29]. Briefly, SPR measurements and ligand immobilisation procedures were conducted at 760 nm in a fully automatic Biacore 2000 instrument (GE-Healthcare GmbH) with four flow cells, with a temperature of 25°C. HBS-EP buffer (0.01 M HEPES [pH 7.4], 0.15 M NaCl, 3 mM EDTA, 0.005 % surfactant P20) (GE-Healthcare GmbH) was used as running buffer. Ligands were coupled to carboxymethylated dextran CM5 chips by conventional carbodiimide chemistry using 200 mM N-ethyl-N0-(3-diethylaminopropyl) carbodiimide and 50 mM N-hydroxysuccinimide. The activation time was 7 min, followed by a 7 min ligand injection. Activation of the remaining active esters was performed by a 7 min injection of ethanolamine/hydrochloride [pH 8.5].

A flow rate of 5 μL/min was used during immobilization and measurement procedures. The ligands were diluted in a ratio of 1:10 or 1:5 in 10 mM acetate buffer [pH 4.5] below the isoelectric point of the protein, thus enhancing the electrostatic interactions between the dextran matrix and the ligands. The contact time was 7 min, which resulted in immobilization levels between 1000 and 10,000 response units (RU). Serum samples were diluted in a ratio of 1:20 and the PMN supernatants were diluted in a ratio of 1:5 with PBS [pH 7.4] (Apoteket AB, Umeå, Sweden). An equal mixture of 1 M NaCl and 10 mM glycine [pH 2], followed by one injection of borate [pH 8.5], was used as a regeneration buffer after each run of sample. A positive and a negative control were included at the beginning and at the end of each sensogram to confirm the reliability of the surfaces. The SPR data of the affinity to the ligands on the sensor chip surface was obtained as response unit (RU).

2.6. Western Blotting

The supernatant of the neutrophil suspensions was filtered through a 10 kDa filter (Millipore) and the concentrate was mixed with Laemmli sample buffer (5×) containing 2-Mercaptoethanol (98°C for 5 min) to denature and reduce the proteins. The proteins were separated using standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to a polyvinylidene difluoride membrane. Unspecific binding was blocked by incubating the membranes in 5% milk-Tris-buffer saline (TBS; consisting of 25 mM Tris base, 150 mM NaCl, 2 mM KCl pH 7.4, and 0.1% Tween-20) for 1 h at RT prior to incubation with a goat polyclonal anti-HGF antibody (1:1000; AF-294-NA; R&D systems) for 1 h at RT. The membranes were thereafter incubated with a polyclonal HRP-conjugated donkey anti-goat antibody (1:1:00; HAF109; R&D systems). Recombinant HGF (294-1A; R&D systems) was used as a positive control.
2.7. Statistical Analysis

The serum data were not normally distributed and therefore statistically analyzed by Mann-Whitney U-test and the medians are presented. The data of the neutrophil experiments were normally distributed and analysed by un-paired or paired student t-test and expressed as mean ± SEM. Software used was Graph Pad Prism version 5, and P < 0.05 was considered to be statistically significant.

3. RESULTS

3.1. The Serum Concentration of HGF

The concentration of HGF, measured by ELISA, was analyzed in serum collected prior to haemodialysis of patients with CRF that had developed to total renal insufficiency, and from healthy controls. The median concentration of HGF was elevated in the patient group (2.25 ng/ml), and differed significantly from the healthy control group (0.98 ng/ml; P < 0.0001) (Figure 1).

3.2. Binding Affinity to Biological Relevant Ligands of HGF

To analyse the ability of HGF to interact with its receptors or other biological relevant ligands important for the biological activity of HGF, the binding affinity to different ligands of HGF (c-Met, D-19, MN and HSPG) was analysed by SPR. The ligands were immobilised on a CM5 chip and the samples were run over the chip surface and binding response was measured in response units (RU). The binding affinity to all ligands tested (Table 1) was significantly reduced in serum from the CRF patients (P ≤ 0.0001 for all ligands) (Figure 2).

3.3. The Release of HGF from Activated Neutrophils

To study the concentration of HGF released by neutrophils (1 × 10^7 cells/ml) isolated from patients with CRF and healthy controls, the cells were stimulated with cytochalasin B (5 μg/ml) and fMLP (10 μM) and the concentration of HGF in the supernatant was measured by ELISA. The fMLP-stimulated neutrophils from CRF patients released a higher amount of HGF (2.16 ± 0.65 ng/ml), compared to controls (1.06 ± 0.386 ng/ml), however, the difference was not statistically significant. Protease inhibitors reduced the amount of HGF in supernatant from stimulated CRF neutrophils (P = 0.039) (Figure 3). There were no differences comparing non-stimulated neutrophils (with or without protease inhibitors) of CRF patients and healthy controls (data not shown).

3.4. The Affinity to HSPG in Supernatant from fMLP-Stimulated Neutrophils

The affinity of HGF released from fMLP-stimulated (10 μM) CRF and healthy control neutrophils (1 × 10^7 cells/ml), respectively, was evaluated by measuring binding affinity to HSPG using SPR. The supernatant of the CRF neutrophil suspension showed a reduced binding affinity to HSPG (12.37 ± 4.2 RU) compared to control neutrophils (45.19 ± 12.03; P < 0.01). The presence of protease inhibitors (pi) increased the binding affinity for HSPG in the suspension of fMLP-stimulated neutrophils in the patient group (P = 0.032), however, the protease inhibitors did not significantly affect the healthy control

![Figure 1](image1.png)

**Figure 1.** Serum concentration of HGF. The serum concentration (ng/ml) of HGF, measured by ELISA, was higher in patients with chronic renal failure (black bars) compared to healthy controls (white bars). Mann-Whitney U-test was used for statistical analysis and the medians are presented (n = 36 for patients and n = 37 for healthy controls). ****P < 0.0001.

![Figure 2](image2.png)

**Figure 2.** Binding affinity to biological relevant ligands of HGF. The binding affinity to different ligands of HGF (c-Met, polyclonal ab D-19, monoclonal anti-HGF ab (MN) and heparan sulphate proteoglycan (HSPG)) was analysed by surface plasmon resonance (SPR) in a Biacore 2000. For statistical analysis Mann-Whitney U-test was used and the medians are presented (n = 36 for patients and n = 30 for healthy controls). ****P < 0.0001, ***P = 0.0001.
samples (Figure 4). When comparing non-stimulated neutrophils of CRF patients and controls there were no differences found, neither did the protease inhibitor cocktail by its own bind to HSPG (data not shown).

3.5. Western Blotting

To visualize the HGF released from CRF and control neutrophils western blot was used. The isolated neutrophils (1 x 10^7 cells/ml) were stimulated with 5 μg/ml cytochalasin B and 10 μM fMLP for 30 min, with and without the addition of protease inhibitor cocktail, and the proteins were concentrated by ultrafiltration. Five blots (including five CRF patients and five healthy controls) were analyzed. The HGF released from the neutrophils of the controls showed bands of 90 kDa, which corresponds to the size of pro-HGF. Some controls also showed weaker bands at 60 kDa, which is the size of the α-chain of HGF. The patient neutrophils varied more in the forms of HGF, showing mostly bands of 60 kDa, one patient also showed bands of 34 kDa, which is the size of the β-chain. No differences were found between samples incubated with or without protease inhibitors (Figure 5).

4. DISCUSSION

In the present study, we have shown that systemic HGF, as well as HGF produced by immune cells, differs significantly between patients with CRF and healthy controls. Regarding to regenerative properties of HGF, this observation suggests a lack of healing of injuries and fibrosis in the course of development of total renal fail-
ure, which might have an impact in development of new therapeutic methods.

Previous studies have shown that administration of recombinant HGF prevents fibrosis and enhances renal regeneration, and that neutralization of endogenous HGF supports fibrosis and worsens tissue regeneration [4,30]. This indicates that despite increased endogenous levels of HGF in patients with CRF, it is insufficient for restoring the homeostatic balance and to heal the tissue and reverse the chronic inflammatory process. We have previously studied the concentration and biological activity of HGF in various infectious diseases, and observed a significant correlation between binding affinity of HGF to HSPG in an in vitro cell injury model [28]. In the present study, we hypothesized that the inflammatory process in patients with CRF is associated with changes in the expression and activity of HGF. Interestingly, this study shows that the biological activity of HGF (measured by binding affinity to the co-receptor HSPG) is markedly reduced in the CRF patients, despite that the amount of HGF measured by ELISA was increased. Additionally, the binding of HGF to the other biological relevant ligands analyzed (c-Met, D-19 and MN) was reduced in the patient group. In previous studies by our group, we found reduced affinity to these ligands by biological inactive HGF, and that HSPG was the strongest indicator of biological activity of HGF in vitro [29] and the biological activity of HGF in an in vivo system [29]. It is possible that the HGF configuration is altered during the chronic inflammation and therefore not able to bind to its ligands/receptors. The western blot analysis showed that neutrophils of the healthy controls mostly secreted pro-HGF and also the α-chain, whereas the neutrophil suspension of the CRF patients varied more in the forms of HGF by showing already proteolytic processed HGF; however, the β-chain was only visible in one patient. The α-chain alone binds with high-affinity to c-Met, although the binding of the α-chain does not activate the receptor [33]. Several proteases in the serum or cell membranes are involved in the activation of single-chain pro-HGF. Perhaps pro-HGF binds to HSPG and is processed in the wounded tissue for further activation of c-Met signaling, however, this is a question for further studies.

Binding to HSPG was previously shown to be important for excretion of excess HGF from blood [24]. A lower binding affinity of HGF to HSPG during chronic inflammation, and a concurrent increased need for regenerative factors, may thus explain the higher systemic amounts of HGF determined by ELISA. In addition, binding to the co-receptor HSPG is essential for the interaction of HGF with its high-affinity receptor (c-Met) and induction of cellular responses [21-23]. Since HGF in CRF patients lacks these binding properties it may suggest reduced regenerative and protective effects in the tissue. The inability of HGF to induce c-Met signalling was previously shown in ulcer secretion of chronic non-healing wounds, and that this HGF was modified and inactivated by neutrophil proteases [17]. The absent c-Met signalling may be explained by the reduced binding to HSPG seen in our study, together with the decreased binding to c-Met. Wilfred et al. [34] also found that neutrophil proteases could inactivate HGF, generating an N-terminal segment and four kringle domains (NK4)-like fragment, which antagonized the biological effect of HGF. Additionally, we found that protease inhibitors positively affected the biological activity of HGF (P = 0.03), but reduced the concentration of HGF (P < 0.04) in the supernatant of stimulated neutrophils from CRF patients. These data suggest that proteases released from neutrophils are involved in the modulation of the expression of HGF, leading to reduced biological activity in the patients. Possibly proteases stimulate HGF release and thereby counteract the effects of proteolytic cleavage of host-molecules and tissue destruction following increased levels of proteases, by activating protease-activating receptors (PARs) [35]. PAR-2 is expressed on neutrophils [36], and activation of PAR-2 by neutrophil proteases may through intracellular mechanisms, including caspase-mediated cleavage of pro-HGF, cause HGF secretion. However, it has not been shown whether neutrophil proteases exert such autocrine effects.

Several studies have highlighted the role of HGF in treatment of injuries of organ and tissues, e.g. kidney [2, 37] and cardiovascular systems [38]. We have previously reported positive effects of exogenous HGF, with high affinity towards HSPG, in the treatment of patients with chronic ulcers [39]. Since mechanisms during the chronic inflammation in CRF may down-regulate the biological activity of HGF, our study suggests that biologically active HGF with high affinity to HSPG may be useful as a therapeutic tool for treatment of CRF.

In summary, we conclude that patients with CRF have a systemic HGF profile reflecting a chronic inflammatory condition with high concentration, but low biological activity, of HGF. These observations might have an impact on future development of strategies for diagnosis, evaluation, and treatment of chronic renal failure.

REFERENCES


[38] Urbanek, K., Rota, M., Casacpera, S., Bearzi, C., Nascimbene, A., De Angelis, A., et al. (2005) Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circulation Research, 97, 663-673. doi:10.1161/01.RES.0000183733.53101.11